Treatment Prediction in PDAC Patients: A Predictive Model for FOLFIRINOX Chemotherapy Response using Random Forest and Integrative Analysis of Blood and Tumor Markers

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a high mortality rate, poor prognosis, and a mere 7.7% 5-year survival rate [1] compared to 65% for all cancer types [2]. Approximately 80% of patients are diagnosed at the advanced stage [3], for which only palliative chemo(radio)therapy remains as treatment option. However,...